Ranibizumab for neovascular age-related macular degeneration - Wikidata - awgldk - TriplyDB

Ranibizumab for neovascular age-related macular degeneration

Ranibizumab for neovascular age-related macular degeneration

http://www.wikidata.org/entity/Q29617549

about

CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard Aflibercept for neovascular age-related macular degeneration Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery Aflibercept for neovascular age-related macular degeneration Anti-vascular endothelial growth factor for neovascular age-related macular degeneration Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopia Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery Interventions for age-related visual problems in patients with stroke Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion Surgery for cataracts in people with age-related macular degeneration Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion Surgery for cataracts in people with age-related macular degeneration Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration Laser photocoagulation for neovascular age-related macular degeneration Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability CCR3 is a target for age-related macular degeneration diagnosis and therapy Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis Long-term safety and efficacy of human-induced pluripotent stem cell (iPS) grafts in a preclinical model of retinitis pigmentosa Nutritional supplements for age-related macular degeneration Ranibizumab and bevacizumab for neovascular age-related macular degeneration MicroRNAs regulate ocular neovascularization Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results A review of Judah Folkman's remarkable achievements in biomedicine Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review Optical Coherence Tomography Angiography in Retinal Diseases Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration Drug discovery in ophthalmology: past success, present challenges, and future opportunities Current therapeutic developments in atrophic age-related macular degeneration Stereotactic radiotherapy for wet age-related macular degeneration: current perspectives Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration Anti-VEGF Therapy and the Retina: An Update Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

P2860

Q21090046-A11796D4-B984-49B6-80FC-4CDD8310DA75 Q21090878-9BBA870F-E7EA-4655-957D-29D75F082C91 Q24186157-3137BF0C-6F65-433D-85B8-50BF6F5D3392 Q24186464-7834342F-3419-42B3-8DE9-1ABED12F3EBA Q24193255-E3522785-B983-47E2-AF93-F75851C1597B Q24194251-4195872A-F27B-4368-A5C2-3EA5A9A68E15 Q24194332-7B0632BE-9913-4633-814D-4A7ADAC24812 Q24200772-369B17F5-3974-4359-B783-1947ADD95D5D Q24201153-D6889254-7C6F-4800-B216-9EA309BB65DA Q24201821-DC7F88FC-6F2D-4ED7-A5A5-90D6D99C7A59 Q24202631-14039851-756E-45BC-AE87-C731EC26A51E Q24234750-102B21C1-9C4B-441C-954A-EEDA210F2BC0 Q24241331-8AB52DB1-8478-4799-BAD8-B26F4F2BF593 Q24243234-701FA02B-146C-4EEE-BA3F-6D75629E7F1E Q24244141-D12C593D-D3C7-4009-802C-189CF96F6B72 Q24311667-46074F32-75D2-4311-B937-8CBF79CDB572 Q24338258-8FCD5A31-C5C7-4F65-AFBA-551867FD21DC Q24569500-D6FD1D8B-94E7-4BB8-B10C-DE13875B1DC3 Q24600170-39F3537D-1D4D-47BA-A521-295E129AD662 Q24603642-18EBE1DD-9674-4D8F-86EA-FA7E75CA94DB Q24616209-483231A7-17E2-4127-98C9-7719B6454E7D Q24631030-FB580C6F-DF37-48AE-8129-27464175E801 Q24633874-2D2AEE12-CF73-4D0B-A2DF-1C10B6555025 Q24652770-62193BFF-2AA6-4990-9B77-D61D3648C7A7 Q24674358-2EB47F5A-83AB-45BA-AD8D-EE6242FDBCFD Q24674561-9EA6CB51-A120-4B6C-93E2-70056C356CAB Q26472033-D1169D41-247C-4425-921E-5A3DE904F57D Q26744068-CC71463A-B884-4C76-B28E-7B25DCD07B94 Q26748464-DFB3AA33-9A8D-4356-9521-D4D266D099C7 Q26748731-8FE0FCC3-51A6-40DB-8EA7-572919E7CB45 Q26749615-51974C66-EA8B-446F-9C14-09F2954CD9AF Q26767095-48E526B6-409A-4B2A-89D2-DCEB61B3376F Q26771522-409677CA-B631-4B2F-A98F-7FA3F4B9411C Q26771638-7842B351-9597-4D35-BAF5-4B3D1EA6E84D Q26778247-01930ECB-7CE8-46BB-AFF0-BE525429DF98 Q26778521-C9D0FCEA-60AD-4DA6-A742-DA39AA97CB60 Q26780543-17A0FACC-DE24-4736-AAC9-396798FA737F Q26784605-E17DE551-E757-4BAE-9CDB-C1F5FD1607D9 Q26785646-CCEA8568-FC6F-4F59-9D8C-169D35E10587 Q26786766-2AF7E60F-6C1D-4088-95E2-DBB04E321598

P2860

Ranibizumab for neovascular age-related macular degeneration

http://www.wikidata.org/entity/Q29617549

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Ranibizumab for neovascular age-related macular degeneration

@ast

Ranibizumab for neovascular age-related macular degeneration

@en

type

label

Ranibizumab for neovascular age-related macular degeneration

@ast

Ranibizumab for neovascular age-related macular degeneration

@en

prefLabel

Ranibizumab for neovascular age-related macular degeneration

@ast

Ranibizumab for neovascular age-related macular degeneration

@en

P1433

Q29617549-B55E960C-B3A2-40E1-B39B-E91C0F95D947

P1476

Q29617549-2F159B9F-73EC-49C3-8195-708EF7A6F78B

P2093

Q29617549-29D5FCE6-0A5C-41D3-8EEC-D4162FEA8F6D

Q29617549-2DF261E7-C45C-478F-947C-16E5164A6E01

Q29617549-34056A2A-179F-4490-9001-3BAF219D9158

Q29617549-536950BE-B99F-43BD-BB22-63DDEA19EEA3

Q29617549-B503581E-8594-48A2-B172-54311CEA49C8

Q29617549-E8CA3E13-88CE-47BB-81FC-BE14F26429FF

Q29617549-F96C77D7-8A0E-4CDC-BBF0-4C158A9266E8

P304

Q29617549-2ED0D94E-1921-413A-B4B3-8FFC19C67F8B

P31

Q29617549-1B52ED81-97F2-4C92-8AF4-13B867FCEE28

P3181

Q29617549-D0EEE32E-EEEB-40A3-8193-477670270EF2

P356

Q29617549-649029C4-74CD-4A32-B9F0-17AE3C5AAC81

P407

Q29617549-E02961D4-974F-4C54-B722-16962DA42930

P433

Q29617549-AFEC5052-A5C2-4D82-AFB8-EFD41205A630

P478

Q29617549-A5426A19-B3F9-4593-985D-02608DBEC366

P577

Q29617549-6CEEEA0F-A147-436A-B802-FABD7F034039

P698

Q29617549-81E97300-538B-44ED-92DB-CC8B7F5B6CE5

P3181

P356

P1433

The New England Journal of Medicine

P1476

Ranibizumab for neovascular age-related macular degeneration

@en

P2093

Boyer DS

http://www.w3.org/2001/XMLSchema#string

Brown DM

http://www.w3.org/2001/XMLSchema#string

Chung CY

http://www.w3.org/2001/XMLSchema#string

Heier JS

http://www.w3.org/2001/XMLSchema#string

Kaiser PK

http://www.w3.org/2001/XMLSchema#string

Kim RY

http://www.w3.org/2001/XMLSchema#string

Rosenfeld PJ

http://www.w3.org/2001/XMLSchema#string

P304

1419-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

451596

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA054481

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

355

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17021318

http://www.w3.org/2001/XMLSchema#string